incretin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
=== Pharmacokinetics === A small amount of rimexolone is absorbed into the systemic circulation. On hourly treatment with the eye drops for a week, blood serum concentrations peaked at 150 pg/ml on average, with many patients remaining below the detection threshold of 80 pg/ml. The elimination half-life from the circulation is estimated at one to two hours; the substance is mainly (over 80%) excreted via the faeces.
In the UK (2013) DMEK is available to patients under the National Health Service at the Royal Shrewsbury Hospital, the Calderdale and Huddersfield NHS Trust, and at Worthing Hospital (Western Sussex Hospitals NHS Foundation Trust). Not all patients with diseased corneas are candidates for endothelial keratoplasty. These procedures correct corneal endothelial failure, but are not able to correct corneal scarring, thinning, or surface irregularity. There is currently limited data on long-term survival of DMEK grafts however the early indications are very positive. An upcoming systematic review will seek to compare the safety and effectiveness of DMEK versus DSAEK in people with corneal failure from Fuchs' endothelial dystrophy and pseudophakic bullous keratopathy.
In 2011, IUPAC evaluated the 2006 results of the Dubna–Livermore collaboration and concluded: "The three events reported for the Z = 118 isotope have very good internal redundancy but with no anchor to known nuclei do not satisfy the criteria for discovery". Because of the very small fusion reaction probability (the fusion cross section is ~0.3–0.6 pb or (3–6)×10−41 m2) the experiment took four months and involved a beam dose of 2.5×1019 calcium ions that had to be shot at the californium target to produce the first recorded event believed to be the synthesis of oganesson. Nevertheless, researchers were highly confident that the results were not a false positive, since the chance that the detections were random events was estimated to be less than one part in 100000. In the experiments, the alpha-decay of three atoms of oganesson was observed. A fourth decay by direct spontaneous fission was also proposed. A half-life of 0.89 ms was calculated: 294Og decays into 290Lv by alpha decay. Since there were only three nuclei, the half-life derived from observed lifetimes has a large uncertainty: 0.89+1.07−0.31 ms.
Sources: en.wikipedia.org
== Early and personal life == Epstein was born in the Bronx, New York, and is Jewish. His parents were Jack (a salesman, born in Toronto, Ontario, Canada) and Evelyn (born in New York City). When he was three years old, his family moved to Hartsdale, New York, and then when he was 13 to the Fairfax District in Los Angeles, California. Epstein said of his father, who refused when Epstein was still a minor to sign a contract on his behalf with the Dodgers: "He wanted me to be a lawyer, rather than a bum."
=== Dairy products === Experiments conducted by introducing the strain ME-3 of L. fermentum into dairy products as a probiotic ingredient revealed that it was able to suppress the reputed contaminants of food such as pathogenic Salmonella spp., Shigella spp., and urinary tract infections that are caused by E. coli and Staphylococcus spp. Also the introduction of L. fermentum strains such as ME-3 in goat milk revealed that it was actually favorable to the host, resulting in an increase in number of beneficial lactobacilli.
After 10 years without any new releases to the series, Gearbox acquired the rights to the Homeworld series from THQ in 2013. Shortly after that the Homeworld Remastered Collection was released in 2015, containing updated High-Definition versions of Homeworld and Homeworld 2 compatible with modern Windows and Mac OS X systems. In September 2013, Gearbox announced a partnership with Blackbird Interactive and licensing the Homeworld-IP for its then-named Hardware: Shipbreakers game. This game later became Homeworld: Deserts of Kharak and was released on January 20, 2016 as a prequel to the original Homeworld game of 1999. On August 30, 2019, Gearbox announced Homeworld 3 which was developed by Blackbird Interactive. The game's development was at least partially funded through a crowdfunding campaign on the Fig platform, and was released May 13, 2024.
==== GnRH modulators ==== GnRH modulators are antigonadotropins and hence functional antiandrogens. In both males and females, gonadotropin-releasing hormone (GnRH) is produced in the hypothalamus and induces the secretion of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. The gonadotropins signal the gonads to make sex hormones such as testosterone and estradiol. GnRH modulators bind to and inhibit the GnRH receptor, thereby preventing gonadotropin release. As a result of this, GnRH modulators are able to completely shut-down gonadal sex hormone production, and can decrease testosterone levels in men and transgender women by about 95%, or to an equivalent extent as surgical castration. GnRH modulators are also commonly known as GnRH analogues. However, not all clinically used GnRH modulators are analogues of GnRH. There are two types of GnRH modulators: GnRH agonists and GnRH antagonists. These medications have the opposite action on the GnRH receptor but paradoxically have the same therapeutic effects. GnRH agonists, such as leuprorelin (Lupron), goserelin (Zoladex), and buserelin (Suprefact), are GnRH receptor superagonists, and work by producing profound desensitization of the GnRH receptor such that the receptor becomes non-functional. This occurs because GnRH is normally released in pulses, but GnRH agonists are continuously present, and this results in excessive downregulation of the receptor and ultimately a complete loss of function.
Sources: en.wikipedia.org
Collagen hybridizing peptide (CHP) staining allows for an easy, direct way to stain denatured collagens of any type (Type I, II, IV, etc.) regardless if they were damaged or degraded via enzymatic, mechanical, chemical, or thermal means. They work by refolding into the collagen triple helix with the available single strands in the tissue. CHPs can be visualized by a simple fluorescence microscope.
== Properties == Industrially produced vinylene carbonate is usually a yellow to brown liquid. By suitable process control and purification steps, a solid product with a melting point of 20-22 °C and a chlorine content below 10ppm can be obtained. Liquid vinylene carbonate turns rapidly yellow even in the absence of light and must be stabilized by the addition of radical scavengers. In solid form, the highly pure substance is long-term stable when stored below 10 °C. Vinylene carbonate dissolves in a variety of solvents such as ethanol, tetrahydrofuran, ethylene carbonate, propylene carbonate, and other dipolar aprotic electrolyte solvents used for lithium ion rechargeable batteries such as dimethyl carbonate, diethyl carbonate and the like.
Romaine (1806), speaker of the New York State Assembly Egbert Benson (1807), member of the Board of Aldermen of New York City and 4th president of the Saint Nicholas Society of the City of New York, nephew of founding father Egbert Benson Henry H. Ross (1808), U.S. congressman from New York Peter Dumont Vroom (1808), U.S. minister to Prussia and governor of New Jersey John Fine (1809), U.S. congressman from New York John Slidell (1810), Confederate minister to France and a central figure of the Trent Affair during the American Civil War; United States senator from Louisiana, brother-in-law of Admiral Matthew C. Perry Charles G. Ferris (1811), U.S. congressman from New York Van Brugh Livingston (1811), chargé d'affaires to Ecuador Nathanael G. Pendleton (1813), U.S. congressman from Ohio Samuel L. Gouverneur (1817), postmaster of New York City, private secretary, nephew, and son-in-law of President James Monroe James I. Roosevelt (1815), U.S. congressman from New York; brother of Cornelius Roosevelt William Beach Lawrence (1818), U.S. chargé d'affaires for Great Britain and acting governor of Rhode Island William F. Havemeyer (1823), three-time mayor of New York City William Duer (1824), U.S.congressman from New York John McKeon (1825): U.S. attorney, Southern District of New York; U.S. congressman from New York Hamilton Fish (1827), US secretary of state; governor of New York; United States senator from New York John Henry Hobart Haws (1827), U.S. congressman from New York John D.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.